Efficacy of baloxavir marboxil as a prophylactic against influenza among in-patients and analysis of influenza virus mutations in their isolates at a Japanese hospital during the 2023-2024 flu season.
Akihide Fujii: Department of Pharmacy, Kawasaki Medical School Hospital 577, Kurashiki Okayama, Matsushima, 701-0192, Japan.
Tomohiro Oishi: Department of Clinical Infectious Diseases, Kawasaki Medical School 577, Kurashiki Okayama, Matsushima, 701-0192, Japan. oo0612@med.kawasaki-m.ac.jp. ORCID
Eisei Kondo: Department of Hematology, Kawasaki Medical School 577, Kurashiki Okayama, Matsushima, 701-0192, Japan.
Zyunko Morihara: Department of Pharmacy, Kawasaki Medical School Hospital 577, Kurashiki Okayama, Matsushima, 701-0192, Japan.
Yuka Ikeda: Department of Pharmacy, Kawasaki Medical School Hospital 577, Kurashiki Okayama, Matsushima, 701-0192, Japan.
Hideyuki Sumida: Department of Pharmacy, Kawasaki Medical School Hospital 577, Kurashiki Okayama, Matsushima, 701-0192, Japan.
Youko Ninomiya: Department of Pharmacy, Kawasaki Medical School Hospital 577, Kurashiki Okayama, Matsushima, 701-0192, Japan.
Satoe Uesugi: Department of Clinical Laboratory, Kawasaki Medical School Hospital 577, Kurashiki Okayama, Matsushima, 701-0192, Japan.
Kimie Okazaki: Department of Clinical Laboratory, Kawasaki Medical School Hospital 577, Kurashiki Okayama, Matsushima, 701-0192, Japan.
Daisuke Yoshioka: Department of Clinical Infectious Diseases, Kawasaki Medical School 577, Kurashiki Okayama, Matsushima, 701-0192, Japan.
Miyoko Kobayashi: Department of Pharmacy, Kawasaki Medical School Hospital 577, Kurashiki Okayama, Matsushima, 701-0192, Japan.
Hideho Wada: Department of Hematology, Kawasaki Medical School 577, Kurashiki Okayama, Matsushima, 701-0192, Japan.
BACKGROUND: Baloxavir marboxil (baloxavir) is a new anti-influenza drug that works as a cap-dependent endonuclease inhibitor. It is approved for prophylactic use against influenza in Japan, but there are few reports on this usage in hospitalized in-patients. It reportedly reduces patient susceptibility to influenza through a mechanism involving amino acid substitution. METHODS: Between August 2023 and July 2024, we investigated the efficacy of baloxavir as a prophylactic against influenza among in-patients at our hospital who had close contact with patients who were infected with influenza viruses in the same rooms. We also investigated the I38T influenza virus variant to baloxavir through samples taken from patients with the virus at the hospital. RESULTS: We enrolled a total of 45 in-patients who had close contact with other patients who were confirmed to be infected with influenza in the same room. Among 34 of them who were prescribed baloxavir prophylactically, none developed influenza within 5 days from their last contact with infected patients. Conversely, among the other 11 who did not use baloxavir, three became infected with influenza within 5 days following contact with the infected patient (P = 0.012). In 85 samples taken from the patients with influenza, 25 were H1N1 types and 60 were H3N2. We detected the I38T variant of the cap-dependent endonuclease-baloxavir complex structure in two of the H3N2-type samples. Both of these patients had contracted influenza from their children. CONCLUSIONS: According to our results, Baloxavir represents an effective prophylactic against influenza for hospitalized in-patients. However, patients with genetic mutations related to decreased susceptibility to influenza, such as I38T variant, should nevertheless exercise higher levels of caution-particularly around children.
